Search

Displaying results 2571 - 2580 of 4438 in total
  1. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]

  2. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line.

  3. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia.

  4. Drug

    Pirenzepine

    go.drugbank.com/drugs/DB00670
    ApprovedWithdrawn

    It is generally well tolerated by patients.

    Products: Gastrozepin Tab 50mg
  5. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  6. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    in position B29 is replaced by proline. … Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

  7. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. … Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by

  8. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.

  9. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Moroctocog alfa is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function. … Moroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia

  10. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.